Phillip, Moshe http://orcid.org/0000-0002-6616-5612
Achenbach, Peter http://orcid.org/0000-0001-6720-2684
Addala, Ananta http://orcid.org/0000-0002-0508-4309
Albanese-O’Neill, Anastasia http://orcid.org/0000-0001-8219-6059
Battelino, Tadej http://orcid.org/0000-0002-0273-4732
Bell, Kirstine J. http://orcid.org/0000-0001-5638-4048
Besser, Rachel E. J. http://orcid.org/0000-0002-4645-6324
Bonifacio, Ezio http://orcid.org/0000-0002-8704-4713
Colhoun, Helen M. http://orcid.org/0000-0002-8345-3288
Couper, Jennifer J. http://orcid.org/0000-0003-4448-8629
Craig, Maria E. http://orcid.org/0000-0001-6004-576X
Danne, Thomas http://orcid.org/0000-0003-0773-6961
de Beaufort, Carine http://orcid.org/0000-0003-4310-6799
Dovc, Klemen http://orcid.org/0000-0001-9201-2145
Driscoll, Kimberly A. http://orcid.org/0000-0002-3006-4633
Dutta, Sanjoy
Ebekozien, Osagie http://orcid.org/0000-0002-8473-249X
Larsson, Helena Elding http://orcid.org/0000-0003-3306-1742
Feiten, Daniel J. http://orcid.org/0009-0005-9922-7305
Frohnert, Brigitte I.
Gabbay, Robert A. http://orcid.org/0000-0003-3541-1486
Gallagher, Mary P. http://orcid.org/0000-0002-5844-2309
Greenbaum, Carla J. http://orcid.org/0000-0003-4451-9800
Griffin, Kurt J. http://orcid.org/0000-0003-2374-0733
Hagopian, William
Haller, Michael J. http://orcid.org/0000-0002-2803-1824
Hendrieckx, Christel http://orcid.org/0000-0002-0075-828X
Hendriks, Emile http://orcid.org/0000-0002-0795-1832
Holt, Richard I. G. http://orcid.org/0000-0001-8911-6744
Hughes, Lucille
Ismail, Heba M. http://orcid.org/0000-0003-0102-0030
Jacobsen, Laura M. http://orcid.org/0000-0002-5144-7836
Johnson, Suzanne B. http://orcid.org/0000-0001-5721-7524
Kolb, Leslie E. http://orcid.org/0000-0003-2803-6788
Kordonouri, Olga http://orcid.org/0000-0001-9563-3537
Lange, Karin http://orcid.org/0000-0002-3636-2025
Lash, Robert W. http://orcid.org/0000-0003-2457-4888
Lernmark, Åke http://orcid.org/0000-0003-1735-0499
Libman, Ingrid http://orcid.org/0000-0002-0255-4555
Lundgren, Markus http://orcid.org/0000-0001-6394-7689
Maahs, David M. http://orcid.org/0000-0002-4602-7909
Marcovecchio, M. Loredana http://orcid.org/0000-0002-4415-316X
Mathieu, Chantal http://orcid.org/0000-0002-4055-5233
Miller, Kellee M.
O’Donnell, Holly K. http://orcid.org/0000-0002-7774-7220
Oron, Tal http://orcid.org/0000-0001-9485-2738
Patil, Shivajirao P. http://orcid.org/0000-0001-9781-4809
Pop-Busui, Rodica http://orcid.org/0000-0002-2042-1350
Rewers, Marian J. http://orcid.org/0000-0003-3829-9207
Rich, Stephen S. http://orcid.org/0000-0003-3872-7793
Schatz, Desmond A. http://orcid.org/0000-0002-1044-5762
Schulman-Rosenbaum, Rifka http://orcid.org/0000-0003-4604-0879
Simmons, Kimber M. http://orcid.org/0000-0003-0560-5773
Sims, Emily K. http://orcid.org/0000-0002-4393-954X
Skyler, Jay S. http://orcid.org/0000-0003-1136-8110
Smith, Laura B. http://orcid.org/0000-0002-3722-7490
Speake, Cate http://orcid.org/0000-0003-1480-4272
Steck, Andrea K. http://orcid.org/0000-0002-5931-9484
Thomas, Nicholas P. B. http://orcid.org/0000-0003-0460-6870
Tonyushkina, Ksenia N. http://orcid.org/0000-0002-6415-8005
Veijola, Riitta http://orcid.org/0000-0002-6557-270X
Wentworth, John M. http://orcid.org/0000-0002-5197-3529
Wherrett, Diane K. http://orcid.org/0000-0003-0629-5316
Wood, Jamie R.
Ziegler, Anette-Gabriele http://orcid.org/0000-0002-6290-5548
DiMeglio, Linda A. http://orcid.org/0000-0002-8033-6078
Article History
First Online: 24 June 2024
Acknowledgements
: The author group wish to thank JDRF for organising the initial expert conference and for providing funding to Robert Brines, Bite Medical Consulting (Cambridge, UK), who supported the author group by collating and compiling author feedback and revisions during the manuscript drafting process. The authors acknowledge the review and endorsement of the following organisations: Advanced Technologies & Treatments for Diabetes (ATTD); the American Association of Clinical Endocrinology (AACE); the American College of Diabetology (ACD); the American Diabetes Association (ADA); the Association of Diabetes Care & Education Specialists (ADCES); the Association for the Endocrine Society; the Australian Diabetes Society (ADS); DiaUnion; the European Association for the Study of Diabetes (EASD); the International Society for Paediatric and Adolescent Diabetes (ISPAD); and JDRF International. Parts of this work were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes Conference, Florence, Italy, 6–9 March 2024, and at the ADA 84th Scientific Sessions, Orlando, FL, USA, 21–24 June 2024.
: MP has received honoraria for participation on advisory boards for AstraZeneca, Eli Lilly, MannKind Corp., Medtronic Diabetes, Pfizer, Sanofi, Dompé, LifeScan, Novo Nordisk, Insulet, Provention Bio, Merck, Ascensia Diabetes Care, Bayer, Embecta and Tandem Diabetes Care, and as a speaker for Eli Lilly, Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi and Ascensia Diabetes Care. MP owns stocks of DreaMed Diabetes and NG Solutions and his institution has received research grant support from Eli Lilly, Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi, DreaMed Diabetes, NG Solutions, Dompé, Lumos, GWave, OPKO, Provention Bio and AstraZeneca, travel expenses from Medtronic Diabetes and Sanofi, and consulting fees from Qulab Medical and Provention Bio. TB served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, Medtronic, Abbott and Indigo Diabetes. TB received honoraria for participating on the speaker’s bureau for Eli Lilly, Novo Nordisk, Medtronic, Abbott, Sanofi, Dexcom, Adventis, AstraZeneca and Roche. TB’s institution has received research grant support and travel expenses from Abbott, Medtronic, Novo Nordisk, Sanofi, Novartis, Sandoz and Zealand Pharma. REJB has received consulting fees from Provention Bio. HMC has received research grant support from IQVIA, JDRF, Chief Scientist Office, Diabetes UK and the UK Medical Research Council (UKRI). HMC has received honorarium from Novo Nordisk and owns shares in Roche Pharmaceuticals and Bayer AG. TD has received honoraria and speaker honoraria and consulting fees and his former institution has received research support from Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk, Provention Bio, Sanofi and Vertex Pharmaceuticals. He is a shareholder in DreamMed. Ltd. KD has received honorarium for participation on advisory boards for Medtronic and Novo Nordisk, and speaker fees from Abbott, Eli Lilly, Novo Nordisk, Medtronic and Pfizer. OE has received research support from MannKind Corp., Medtronic Diabetes, Abbott, Dexcom, Eli Lilly Pharmaceuticals, Janssen Pharmaceuticals and Vertex Pharmaceuticals. OE has also participated on advisory boards for Medtronic and Sanofi. OE has received consultation and speaker fees from Medtronic Diabetes, Sanofi and Vertex Pharmaceuticals. All financial support from industry for OE has been through his organisation, T1D Exchange. RAG has received honorarium from Lark, Sweetch, StartUp Health, Vida and Valendo. CJG’s institution received payment from Sanofi as a clinical trial centre. KJG has received sponsored travel from JDRF. WH received grant/consultancy fees from Sanofi/Provention Bio. MJH has received grants or consultancy fees from Sanofi, MannKind Corp. and SAB Biotherapeutics and is a stock options holder of SAB Biotherapeutics. RIGH has received honoraria for speaking from EASD, Eli Lilly, ENCORE, Liberum, Novo Nordisk, Rovi and Boehringer Ingelheim. RIGH has received conference funding from Novo Nordisk and Eli Lilly. OK has received honoraria and lecture fees from Sanofi, Dexcom and Medtronic. RWL has received a consultancy fee from Cigna Insurance. DMM has received research support from the National Institutes of Health, JDRF, National Science Foundation and the Leona M. and Harry B. Helmsley Charitable Trust, and his institution has had research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Tandem Diabetes Care and Roche. CM serves or has served on advisory panels for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Boehringer Ingelheim, Roche, Medtronic, Imcyse, Insulet, Biomea Fusion and Vertex Pharmaceuticals. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics; CM serves or has served on speakers’ bureaus for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM is president of EASD. All external support of EASD is to be found on . HKO’D received compensation from Sanofi for attending their advisory board and for speaking at ADA 84th Scientific Sessions. RP-B has received payment or honoraria from Bayer, Lexicon Pharma, Novo Nordisk, Averitas Pharma, Nevro, Roche and Medtronic. MJR has received honoraria and grants from Sanofi. KMS has received consultancy fees, grants or honoraria from Provention Bio and Sanofi. EKS has received consulting fees from Sanofi and DRI Healthcare and has received payment for lectures from Health Matters CME, Medscape, Med Learning Group LLC and the ADA. JSS has been a scientific advisory board member for 4Immune, ActoBiotics, Avotres and Quell Therapeutics. JSS has been a data safety board member for Imcyse and Provention Bio and is a member of the board of directors for SAB Therapeutics. JSS has been an advisor or consultant for ImmunoMolecular Therapeutics, Novo Nordisk, Remedy Plan Inc, SAB Therapeutics and Sanofi. JSS has shares in or is an option holder for 4Immune, Avotres, ImmunoMolecular Therapeutics, Remedy Plan Inc and SAB Therapeutics. CS has received research funding from Cour Pharmaceuticals and consultancy fees from Sanofi and GentiBio. LAD has received research support to their institution from Dompé, Lilly, MannKind Corp., Medtronic, Provention/Sanofi, and Zealand and consulting fees from Vertex Pharmaceuticals and Abata. LAD has a patent pending for use of difluoromethylornithine (DFMO). All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All listed authors were responsible for drafting the consensus guidance article and reviewing it critically for important intellectual content. All authors approved the final draft version of the manuscript submitted for publication.